Both COMT rs4680 high-activity G-allele and rs4818 C/G genotype were significantly associated with decreased fatigue severity and improved fatigue-distressed quality of life among cancer survivors participating in a trial of the non-deceptive administration of placebo pills. This evidence concerns the gene COMT and cancer.